• Users Online: 113
  • Print this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

Predictable repeatability issues with GeneXpert-Xpert MTB/RIF (version 4) derived rifampicin resistant tuberculosis results from South India: Appreciating the limits of a technological marvel!

Sanker Praveen, Kottuthodi Ramya Puthukkudi, Ambika Anusree Puthenveettil, Santhosh Vishnu T, Balakrishnan Ravikrishnan, Mrithunjayan Sunil Kumar, Moosan Hisham

Year : 2017| Volume: 1| Issue : 1 | Page no: 76-80

   This article has been cited by
 
1 Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
Fengmin Huo,Yifeng Ma,Rongmei Liu,Liping Ma,Shanshan Li,Guanglu Jiang,Fen Wang,Yuanyuan Shang,Lingling Dong,Yu Pang
Open Forum Infectious Diseases. 2020; 7(8)
[Pubmed]  [Google Scholar] [DOI]
2 Interpreting very low Mycobacterium tuberculosis detected on Xpert Mycobacterium tuberculosis/rifampicin
Kanchan Ajbani,Swapna Naik,Mubin Kazi,Anjali Shetty,Camilla Rodrigues
Lung India. 2019; 36(6): 555
[Pubmed]  [Google Scholar] [DOI]
3 Validation of the GenoType® MTBDRplus Ver 2.0 assay for detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates at UZCHS-CTRC TB research laboratory
Stephen Stephen,Donhodzo Muzhizhizhi,Nicholas Dhibi,Tinashe Chidemo,Wadzanai Samaneka,TagumaAllen Matubu,JamesGita Hakim,ZvavaheraMike Chirenje
International Journal of Mycobacteriology. 2019; 8(1): 83
[Pubmed]  [Google Scholar] [DOI]
4 Assessment of diagnostic accuracy of GeneXpert Mycobacterium tuberculosis/rifampicin in diagnosis of pulmonary tuberculosis in Kosovo
Rrezarta Bajrami,Gjyle Mulliqi,Arsim Kurti,Greta Lila,Lul Raka
Biomedical and Biotechnology Research Journal (BBRJ). 2018; 2(3): 191
[Pubmed]  [Google Scholar] [DOI]

 

Read this article